Developer docs
API playgroundTry for free, no card

Search company profiles

UNION therapeutics A/S

Full company profile

uuid000983z

Namestring
UNION therapeutics A/S
Legal namestring
UNION therapeutics A/S
Company typeenum
Private
Founded yearint
2011
Descriptiontext

UNION therapeutics A/S is a privately held, clinical-stage pharmaceutical development company headquartered in Hellerup, Denmark, focused on advancing oral therapies within immunology. The company pursues a pipeline-in-a-drug strategy around its lead asset orismilast, a next-generation, high-potency PDE4 inhibitor that selectively targets the PDE4B and PDE4D subtypes linked to inflammation. Orismilast demonstrates potent inhibition of Th1, Th2 and Th17 pathways, acting early in the inflammation cascade to deliver broad anti-inflammatory effects at higher potency than previously marketed pan-PDE4 inhibitors while retaining the class's established safety profile.

The company is advancing oral orismilast across four immunologic indications: atopic dermatitis, hidradenitis suppurativa, psoriasis and ulcerative colitis, supported by FDA Fast Track designations for AD and HS and a cleared U.S. IND. Clinical evidence includes the ADESOS Phase 2b study in AD showing statistically significant IGA 0/1 responses at Week 16, the IASOS Phase 2b study in psoriasis reporting 39.5%-49.0% PASI75 rates, the OSIRIS study in HS where 67% of treatment-completers achieved HiSCR50, and the UCORIS Phase 2a investigator-initiated study in UC reporting complete remission in three patients. UNION previously developed a niclosamide nasal spray for COVID-19 prophylaxis but discontinued the program in June 2023 after the PROTECT-V study failed its primary endpoint.

Commercially, UNION is pre-revenue on a product basis. Historical inflows (DKK 34.4m disclosed revenue in 2022) derive from licensing milestones, notably from the 2021 strategic partnership with Innovent Biologics covering Mainland China, Hong Kong, Macau and Taiwan. The company is funded by founders, management, family offices and private investors, with cumulative equity of approximately DKK 381m raised across 2021-2023, USD 4.0m in licensing milestone payments, a DKK 79.5m venture debt facility with the European Investment Bank, and DKK 45m of convertible debt converted to equity. R&D investment declined from DKK 186.4m in 2022 to DKK 60.8m in 2024 as Phase 2 programs completed, with cash and equivalents standing at DKK 37.6m at year-end 2024. The company is led by Co-CEOs Kim Kjøller and Rasmus Toft-Kehler, CFO Morten Boesen, and CSO Morten Sommer, with Stig Løkke Pedersen as Chair of the Board.

Short descriptiontext

UNION therapeutics A/S is a privately held, clinical-stage Danish pharmaceutical company developing orismilast, an oral next-generation PDE4B/D selective inhibitor, for atopic dermatitis, hidradenitis suppurativa, psoriasis, and ulcerative colitis, funded by equity, venture debt, and licensing milestones.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersHellerup, Denmark
HQ citystring
Hellerup
HQ countrystring
Denmark
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
PDE4 inhibitor development, inflammatory disease therapeutics, clinical-stage pharmaceuticals, immunology drug development, atopic dermatitis treatment
Industry2 codes
PRIMARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAIACAL
Dermatology Specialty Pharmaceuticals
NAICS code1 code
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Inflammatory Disease Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Development
TypeLicensing Royalties
Description

UNION therapeutics is a privately held, clinical-stage pharmaceutical development company. As a pre-commercial biotech, the company does not currently generate product revenue. Revenue historically came from licensing agreements and milestone payments (USD 4.0m in milestone payments from licensing agreements). The company raises capital through equity financing and non-dilutive sources to fund clinical development.

uniontherapeutics.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

UNION therapeutics is a clinical-stage pharmaceutical company developing orismilast, a next-generation, high-potency selective inhibitor of PDE4B and PDE4D, as an oral treatment for chronic inflammatory diseases including atopic dermatitis, hidradenitis suppurativa, psoriasis, and ulcerative colitis. The company pursues a pipeline-in-a-drug strategy, leveraging orismilast's broad anti-inflammatory activity across multiple immune pathways and indications, and currently funds development through equity financing, EIB venture debt, and milestone payments from a regional licensing partnership.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Phase 2b ADESOS study: IGA 0/1 response at Week 16 achieved statistical significance for all dose arms (20mg: 26.3%, 30mg: 24.3%, 40mg: 30.9% vs placebo 9.5%, all p<0.05)
+3 more records
Product overview1 text field

UNION therapeutics is a privately held, clinical-stage pharmaceutical development company advancing novel treatment options within immunology. The company's lead product is orismilast, a next-generation high potency PDE4B/D inhibitor being developed as an oral treatment across multiple inflammatory indications including atopic dermatitis, hidradenitis suppurativa, psoriasis, and ulcerative colitis. The company previously developed niclosamide nasal spray for COVID-19 prophylaxis but discontinued this program after clinical trial results did not meet endpoints. UNION operates with a pipeline-in-a-drug strategy, leveraging orismilast's broad anti-inflammatory properties across multiple disease areas.

Product and service1 record
1Orismilast
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Strategic partnership with Innovent Biologics for the development of orismilast in Mainland China, Hong Kong, Macau, and Taiwan. UNION granted rights to Innovent for clinical development and commercialization in these territories, representing a significant licensing agreement that provides milestone payments and potential royalties.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Arcutis is a clinical/commercial-stage dermatology company with a PDE4 inhibitor (roflumilast cream — Zoryve) approved for psoriasis and in development for atopic dermatitis. Highly comparable PDE4-mechanism focus on inflammatory skin diseases targeting the same indications UNION is pursuing.

TypeDirect peer
Description

Incyte developed Opzelura (topical ruxolitinib) and has a deep immunology pipeline including JAK inhibitors for AD, vitiligo, and HS. Comparable immunology-focused mid-cap biopharma with overlapping dermatology indications and a similar "oral/skin" commercial strategy.

TypeBroad incumbent
Description

Amgen owns Otezla (apremilast) — the leading approved oral PDE4 inhibitor for psoriasis, Behçet's, and indications adjacent to UNION's. As the established oral PDE4 incumbent, it directly competes with orismilast's positioning and represents the principal efficacy/safety benchmark.

TypeBroad incumbent
Description

AbbVie's Rinvoq (upadacitinib) is an oral JAK inhibitor approved across AD, psoriasis, UC, and other immunology indications. Competes with orismilast in every primary indication UNION is pursuing and sets the bar for oral efficacy.

TypeBroad incumbent
Description

Dupixent (dupilumab) is the market-leading injectable biologic for AD, HS, asthma, and other Type 2 inflammatory diseases. Sets the efficacy benchmark and dominant commercial standard that oral orismilast must compete against in the same indications.

TypeEmerging player
Description

MoonLake is developing an IL-17 (sonelokimab) nanobody for HS and other dermatology indications. Comparable emerging immunology-focused biotech with a lead asset directly overlapping UNION's HS program.

TypeEmerging player
Description

Clinical-stage immunology company developing IL-36 and IL-17 antagonists for hidradenitis suppurativa and other inflammatory skin conditions. Competes directly in HS and shares the focused-immunology emerging-biotech profile.

TypeBroad incumbent
Description

Lilly's Olumiant (baricitinib) is an oral JAK inhibitor approved for AD and other immunology indications. Direct comparator in atopic dermatitis oral therapy positioning alongside Rinvoq.

TypeBroad incumbent
Description

Novartis's Cosentyx (secukinumab) is an IL-17A inhibitor approved for psoriasis, HS, and other immunology indications. Sets the efficacy/safety bar in psoriasis and HS that oral orismilast must differentiate against.

TypeRegional player
Description

European (Belgian) clinical-stage biotech developing selective kinase and inflammation-targeted therapies for immunology indications including UC. Comparable European mid-cap biotech with similar size, strategic positioning, and immunology-focused pipeline.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

UNION therapeutics A/S

Inflammatory Disease Therapeuticsuniontherapeutics.com

UNION therapeutics A/S is a privately held, clinical-stage Danish pharmaceutical company developing orismilast, an oral next-generation PDE4B/D selective inhibitor, for atopic dermatitis, hidradenitis suppurativa, psoriasis, and ulcerative colitis, funded by equity, venture debt, and licensing milestones.

What UNION therapeutics A/S does

UNION therapeutics A/S is a privately held, clinical-stage pharmaceutical development company headquartered in Hellerup, Denmark, focused on advancing oral therapies within immunology. The company pursues a pipeline-in-a-drug strategy around its lead asset orismilast, a next-generation, high-potency PDE4 inhibitor that selectively targets the PDE4B and PDE4D subtypes linked to inflammation. Orismilast demonstrates potent inhibition of Th1, Th2 and Th17 pathways, acting early in the inflammation cascade to deliver broad anti-inflammatory effects at higher potency than previously marketed pan-PDE4 inhibitors while retaining the class's established safety profile.

The company is advancing oral orismilast across four immunologic indications: atopic dermatitis, hidradenitis suppurativa, psoriasis and ulcerative colitis, supported by FDA Fast Track designations for AD and HS and a cleared U.S. IND. Clinical evidence includes the ADESOS Phase 2b study in AD showing statistically significant IGA 0/1 responses at Week 16, the IASOS Phase 2b study in psoriasis reporting 39.5%-49.0% PASI75 rates, the OSIRIS study in HS where 67% of treatment-completers achieved HiSCR50, and the UCORIS Phase 2a investigator-initiated study in UC reporting complete remission in three patients. UNION previously developed a niclosamide nasal spray for COVID-19 prophylaxis but discontinued the program in June 2023 after the PROTECT-V study failed its primary endpoint.

Commercially, UNION is pre-revenue on a product basis. Historical inflows (DKK 34.4m disclosed revenue in 2022) derive from licensing milestones, notably from the 2021 strategic partnership with Innovent Biologics covering Mainland China, Hong Kong, Macau and Taiwan. The company is funded by founders, management, family offices and private investors, with cumulative equity of approximately DKK 381m raised across 2021-2023, USD 4.0m in licensing milestone payments, a DKK 79.5m venture debt facility with the European Investment Bank, and DKK 45m of convertible debt converted to equity. R&D investment declined from DKK 186.4m in 2022 to DKK 60.8m in 2024 as Phase 2 programs completed, with cash and equivalents standing at DKK 37.6m at year-end 2024. The company is led by Co-CEOs Kim Kjøller and Rasmus Toft-Kehler, CFO Morten Boesen, and CSO Morten Sommer, with Stig Løkke Pedersen as Chair of the Board.

UNION therapeutics A/S firmographics

Firmographics
Name
UNION therapeutics A/S
Legal name
UNION therapeutics A/S
Website
https://uniontherapeutics.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
1–10 employees
Short description
UNION therapeutics A/S is a privately held, clinical-stage Danish pharmaceutical company developing orismilast, an oral next-generation PDE4B/D selective inhibitor, for atopic dermatitis, hidradenitis suppurativa, psoriasis, and ulcerative colitis, funded by equity, venture debt, and licensing milestones.
Ownership category
akta.pro rank

UNION therapeutics A/S industry classification

Industry
Product category
Inflammatory Disease Therapeutics
NAICS
Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAIACAL
Dermatology Specialty Pharmaceuticals

Keywords

  • PDE4 inhibitor development
  • Inflammatory disease therapeutics
  • Clinical-stage pharmaceuticals
  • Immunology drug development
  • Atopic dermatitis treatment

Where UNION therapeutics A/S is headquartered

Location

Headquarters

HQ city
Hellerup
HQ country
Denmark
HQ region
Europe

Offices1 record

Markets served

UNION therapeutics A/S business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Development: UNION therapeutics is a privately held, clinical-stage pharmaceutical development company. As a pre-commercial biotech, the company does not currently generate product revenue. Revenue historically came from licensing agreements and milestone payments (USD 4.0m in milestone payments from licensing agreements). The company raises capital through equity financing and non-dilutive sources to fund clinical development.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

UNION therapeutics A/S product offering

Product offering

Core offering

UNION therapeutics is a clinical-stage pharmaceutical company developing orismilast, a next-generation, high-potency selective inhibitor of PDE4B and PDE4D, as an oral treatment for chronic inflammatory diseases including atopic dermatitis, hidradenitis suppurativa, psoriasis, and ulcerative colitis. The company pursues a pipeline-in-a-drug strategy, leveraging orismilast's broad anti-inflammatory activity across multiple immune pathways and indications, and currently funds development through equity financing, EIB venture debt, and milestone payments from a regional licensing partnership.

Product overview

UNION therapeutics is a privately held, clinical-stage pharmaceutical development company advancing novel treatment options within immunology. The company's lead product is orismilast, a next-generation high potency PDE4B/D inhibitor being developed as an oral treatment across multiple inflammatory indications including atopic dermatitis, hidradenitis suppurativa, psoriasis, and ulcerative colitis. The company previously developed niclosamide nasal spray for COVID-19 prophylaxis but discontinued this program after clinical trial results did not meet endpoints. UNION operates with a pipeline-in-a-drug strategy, leveraging orismilast's broad anti-inflammatory properties across multiple disease areas.

Differentiator

Problem solved

Functional benefit

Products and services

  • Orismilast

Quantifiable outcome

  • Phase 2b ADESOS study: IGA 0/1 response at Week 16 achieved statistical significance for all dose arms (20mg: 26.3%, 30mg: 24.3%, 40mg: 30.9% vs placebo 9.5%, all p<0.05)
  • +3 more outcomes

Companies that use UNION therapeutics A/S

Customer profile

Segments4 records

Ideal customer profiles2 records

UNION therapeutics A/S technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

UNION therapeutics A/S partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Innovent BiologicscoreStrategic or Co-development Partner · 1 January 2021Strategic partnership with Innovent Biologics for the development of orismilast in Mainland China, Hong Kong, Macau, and Taiwan. UNION granted rights to Innovent for clinical development and commercialization in these territories, representing a significant licensing agreement that provides milestone payments and potential royalties.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

UNION therapeutics A/S competitors and assessment

Company assessment

Direct peers

  • Arcutis Biotherapeutics: Arcutis is a clinical/commercial-stage dermatology company with a PDE4 inhibitor (roflumilast cream — Zoryve) approved for psoriasis and in development for atopic dermatitis. Highly comparable PDE4-mechanism focus on inflammatory skin diseases targeting the same indications UNION is pursuing.
  • Incyte Corporation: Incyte developed Opzelura (topical ruxolitinib) and has a deep immunology pipeline including JAK inhibitors for AD, vitiligo, and HS. Comparable immunology-focused mid-cap biopharma with overlapping dermatology indications and a similar "oral/skin" commercial strategy.

Broad incumbents

  • Amgen (Otezla): Amgen owns Otezla (apremilast) — the leading approved oral PDE4 inhibitor for psoriasis, Behçet's, and indications adjacent to UNION's. As the established oral PDE4 incumbent, it directly competes with orismilast's positioning and represents the principal efficacy/safety benchmark.
  • AbbVie (Rinvoq): AbbVie's Rinvoq (upadacitinib) is an oral JAK inhibitor approved across AD, psoriasis, UC, and other immunology indications. Competes with orismilast in every primary indication UNION is pursuing and sets the bar for oral efficacy.
  • Sanofi/Regeneron (Dupixent): Dupixent (dupilumab) is the market-leading injectable biologic for AD, HS, asthma, and other Type 2 inflammatory diseases. Sets the efficacy benchmark and dominant commercial standard that oral orismilast must compete against in the same indications.
  • Eli Lilly (Olumiant): Lilly's Olumiant (baricitinib) is an oral JAK inhibitor approved for AD and other immunology indications. Direct comparator in atopic dermatitis oral therapy positioning alongside Rinvoq.
  • Novartis (Cosentyx): Novartis's Cosentyx (secukinumab) is an IL-17A inhibitor approved for psoriasis, HS, and other immunology indications. Sets the efficacy/safety bar in psoriasis and HS that oral orismilast must differentiate against.

Emerging players

  • MoonLake Immunotherapeutics: MoonLake is developing an IL-17 (sonelokimab) nanobody for HS and other dermatology indications. Comparable emerging immunology-focused biotech with a lead asset directly overlapping UNION's HS program.
  • AnaptysBio: Clinical-stage immunology company developing IL-36 and IL-17 antagonists for hidradenitis suppurativa and other inflammatory skin conditions. Competes directly in HS and shares the focused-immunology emerging-biotech profile.

Regional players

  • Galapagos NV: European (Belgian) clinical-stage biotech developing selective kinase and inflammation-targeted therapies for immunology indications including UC. Comparable European mid-cap biotech with similar size, strategic positioning, and immunology-focused pipeline.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights6 records

Customer concentration

UNION therapeutics A/S social profiles

Digital presence

UNION therapeutics A/S compliance and trust

Trust signal

Compliance2 records

UNION therapeutics A/S financial estimates

Financial estimate

Revenue estimate

Valuation estimate

UNION therapeutics A/S leadership team

Management profile

Number of profiles

Profiles6 records

UNION therapeutics A/S funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

UNION therapeutics A/S M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about UNION therapeutics A/S

What does UNION therapeutics A/S do?

UNION therapeutics is a clinical-stage pharmaceutical company developing orismilast, a next-generation, high-potency selective inhibitor of PDE4B and PDE4D, as an oral treatment for chronic inflammatory diseases including atopic dermatitis, hidradenitis suppurativa, psoriasis, and ulcerative colitis. The company pursues a pipeline-in-a-drug strategy, leveraging orismilast's broad anti-inflammatory activity across multiple immune pathways and indications, and currently funds development through equity financing, EIB venture debt, and milestone payments from a regional licensing partnership.

Is UNION therapeutics A/S a public or private company?

UNION therapeutics A/S is a private company. It is classified as venture growth investor backed and is currently operating.

When was UNION therapeutics A/S founded?

UNION therapeutics A/S was founded in 2011. It employs 1 to 10 people.

Where is UNION therapeutics A/S based?

UNION therapeutics A/S is headquartered in Hellerup, Denmark, in the Europe region.

How does UNION therapeutics A/S make money?

One revenue line is on record: pharmaceutical Development.

Who are UNION therapeutics A/S's main competitors?

Direct peers on record are Arcutis Biotherapeutics and Incyte Corporation. Broad incumbents are Amgen (Otezla), AbbVie (Rinvoq), Sanofi/Regeneron (Dupixent), Eli Lilly (Olumiant) and Novartis (Cosentyx). Emerging players are MoonLake Immunotherapeutics and AnaptysBio. Galapagos NV is listed as a regional player.

Does UNION therapeutics A/S have an API?

No public API is recorded for UNION therapeutics A/S.

What industry is UNION therapeutics A/S in?

UNION therapeutics A/S's product category is Inflammatory Disease Therapeutics. Its primary akta.pro industry code is HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals, with a secondary code of HLAIACAL, Dermatology Specialty Pharmaceuticals. Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
news.cision.comUNION therapeutics announces publication of biomarker modulation profile of orismilast using novel approach with tape-stripping and Olink technologyUNION therapeutics A/S announced publication of biomarker data from the IASOS Phase 2b study demonstrating that its drug candidate orismilast, a PDE4 B/D inhibitor, significantly reduced key disease-driving cytokines in psoriasis patients at Week 16, with reductions of 51-52% in IL-17A, 41-54% in CCL20, and 60-66% in TNFα across the active treatment arms. The study used a novel combination of tape-stripping and Olink technology to analyze 71 skin proteins, with 32 found to be upregulated at baseline. The findings support the company's plans for a Phase 2b study in hidradenitis suppurativa and support the broader potential of orismilast for treating inflammatory diseases with multiple immune axes involved.PR NewswireUNION therapeutics announces successful completion of the ADESOS Phase 2b study and presentation of data at the RAVE Conference 2024UNION therapeutics announced successful completion of the ADESOS Phase 2b study evaluating orismilast as an oral treatment for moderate-to-severe atopic dermatitis in 233 patients. The topline results have been selected for oral presentation at the RAVE Conference 2024 in Chicago on June 8-10. The company is progressing orismilast to Phase 3 development with an End of Phase 2 meeting with the FDA already scheduled.PR NewswireUNION therapeutics announces successful completion of the ADESOS Phase 2b study and presentation of data at the RAVE Conference 2024UNION therapeutics announced successful completion of the ADESOS Phase 2b study evaluating orismilast as an oral treatment in 233 patients with moderate-to-severe atopic dermatitis, with topline results selected for oral presentation at the RAVE Conference 2024 in Chicago. The company has scheduled an End of Phase 2 meeting with the FDA to discuss advancing the orismilast development program into Phase 3 studies. Orismilast is a next-generation PDE4B/D selective inhibitor also showing positive results in psoriasis and hidradenitis suppurativa, with the FDA having granted Fast Track designation for moderate-to-severe AD.PR NewswireUNION therapeutics to present at 7th Annual Dermatology Drug Development Summit in BostonUNION therapeutics A/S, a privately held Danish pharmaceutical development company focused on immunology and infectious disease, announced that CEO Dr. Kim D. Kjøller will present at the 7th Annual Dermatology Drug Development Summit in Boston from October 31 to November 2, 2023. Dr. Kjøller will discuss clinical trial efficacy challenges and progress in hidradenitis suppurativa, including data from the OSIRIS proof-of-concept study of oral orismilast presented at the EADV Congress 2023.PR NewswireUNION therapeutics announces presentation of new data on orismilast at the EADV Congress 2023UNION therapeutics announced the acceptance of late-breaking data presentations on its drug candidate orismilast at the European Academy of Dermatology and Venerology (EADV) Congress 2023 in Berlin. The presentations will cover proof-of-concept results from the OSIRIS study for hidradenitis suppurativa and efficacy data from the Phase 2b IASOS study for psoriasis. This announcement highlights the company's progress in advancing orismilast, which has received Fast Track designation from the FDA for treating moderate to severe atopic dermatitis and hidradenitis suppurativa.PR NewswireUNION therapeutics announces presentation of new data on orismilast at the EADV Congress 2023UNION therapeutics announced late-breaking oral presentation and e-posters presenting new clinical data on oral orismilast for hidradenitis suppurativa and psoriasis at the EADV Congress 2023 in Berlin, Germany. The data comes from the OSIRIS investigator-initiated proof-of-concept study and the IASOS Phase 2b study, both of which reported positive topline results in 2023. Orismilast, a next-generation PDE4B/D selective inhibitor, has received FDA Fast Track designation for moderate-to-severe atopic dermatitis and hidradenitis suppurativa, with UNION pursuing best or first-in-class positioning across these dermatological conditions.PR NewswireUNION therapeutics to present at 4th Annual Dermatology Drug Development Summit EuropeUNION therapeutics A/S announced that its CEO, Dr. Kim D. Kjøller, will present at the 4th Annual Dermatology Drug Development Summit Europe in Berlin, Germany, on May 24, 2023. Dr. Kjøller will discuss the hidradenitis suppurativa treatment landscape and moderate a pre-conference workshop on dermatological development strategies on May 22, 2023.PR NewswireUNION therapeutics to present at 4th Annual Dermatology Drug Development Summit EuropeUNION therapeutics A/S, a privately held Danish pharmaceutical development company focused on immunology and infectious disease, announced that its CEO Dr. Kim D. Kjøller will present at the 4th Annual Dermatology Drug Development Summit Europe in Berlin, Germany, on May 22-24, 2023. Dr. Kjøller will discuss the hidradenitis suppurativa (HS) treatment landscape and moderate a pre-conference workshop on dermatological development strategies. The company, headquartered in Hellerup, Denmark, is positioning this conference appearance as an opportunity to showcase its expertise in immunology and dermatology.PR NewswireUNION therapeutics to participate at Kempen Life Science ConferenceUNION therapeutics announced its participation at the Kempen Life Science Conference on April 25-26, 2023, in Amsterdam. The company, a privately held pharmaceutical development firm focused on immunology and infectious disease, will be present at the event.PR NewswireUNION therapeutics receives FDA Fast Track designation for oral orismilast for the treatment of moderate to severe hidradenitis suppurativaUNION therapeutics A/S announced that the US Food and Drug Administration (FDA) has granted Fast Track designation to oral orismilast for the treatment of moderate to severe hidradenitis suppurativa (HS), a chronic inflammatory skin disease with very limited treatment options. The designation enables more frequent FDA interactions, eligibility for rolling review and priority review, and underscores the unmet medical need in this therapeutic area. UNION is also developing orismilast for atopic dermatitis and psoriasis, and has an ongoing Phase 2a study (OSIRIS) with a treatment extension granted by Danish authorities.